Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder

Seoul National University

Status and phase

Withdrawn

Phase 4

Conditions

Anxiety Disorder

Treatments

Drug: alprazolam

Drug: buspirone+alprazolam

Study type

Interventional

Funder types

Other

Identifiers

NCT01546896

bsp2010

Details and patient eligibility

About

This research aims to investigate the efficacy and safety of buspirone in treating generalized anxiety disorder with depressive symptoms and to evaluate its neuroprotective effects using magnetic resonance imaging.

Sex

All

Ages

20 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Patient Inclusion Criteria:

Men and women aged between 20 and 65
Diagnosis of generalized anxiety disorder as assessed by Structured Clinical Interview for DSM-IV (SCID-IV)
Depressive symptom scores measured by Hamilton Depression Rating Scale at screening and baseline assessments: >=8 and <=16

Healthy Control Subject Inclusion Criteria

Healthy men and women aged between 20 and 65

Exclusion Criteria:

Presence of any major physical or neurological illness (e.g.， head trauma, epilepsy， seizure， stroke， cerebral tumor， multiple sclerosis，cerebrovascular disease， narrow-angle glaucoma， drug hypersensitivity， etc.)
Drug abuse in past 3 months
Contraindications to magnetic resonance imaging (e.g., pacemaker implantation，claustrophobia, etc.)
Diagnosis of any Axis I disorder other than generalized anxiety disorder or presence of symptoms requiring hospitalization
Major depressive episode during past 12 months
Depressive symptom scores measured by Hamilton Depression Rating Scale: >=17
Women who are pregnant, breastfeeding, or planning pregnancy
Contraindications to drugs used in the study (e.g., allergy, intolerance, etc.)
Unstable medical illness or severe abnormality in laboratory test at screening assessment
Use of psychoactive medications that may affect brain imaging findings
Intelligence quotient below 80